Clinical trial
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid…
NCT00101595 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00101595 |
|---|---|
| Title | Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
| Official title | A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 96 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jan 13, 2005 |
| Last update posted | Apr 14, 2011 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Israel, Italy and 8 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: